XXXX : response to @entity230 and immunosuppression.

@entity1 @entity644 @entity8 @entity230 @entity101 @entity500 @entity229 @entity786 @entity177 @entity1985
In a retrospective study, the clinical course of 23 adult @entity1 with documented idiopathic @entity8 was reviewed. These @entity1 included 16 @entity1 and 7 @entity1 , who were followed for a period of as long as 9 years, 22 @entity1 (95.7%) were @entity1985 ( @entity644 of 3 g or more in 24 h) and 6 (26%) were @entity101 . 5 @entity1 were treated with @entity229 alone, 12 with @entity229 and @entity786 , 2 with @entity229 and @entity500 and 4 received no treatment. 18 @entity1 achieved complete remission (78.3%). 16 of these (88.9%) were treated with @entity229 , or @entity229 and @entity786 or @entity500 , and the remaining remitted spontaneously. In 3 additional @entity1 , @entity644 improved with treatment with @entity229 and immunosuppression but remained in the @entity1985 range in 2, and fell to 1.8 g/day in 1. @entity1 who failed to respond to @entity230 showed remarkable improvement when therapy with @entity786 was added. Of the 4 @entity1 not treated, 2 underwent spontaneous remission and 2 developed @entity177 . These results suggest a beneficial effect of @entity230 in the treatment of @entity8 , and suggests further that @entity786 may be effective in @entity1 not responding to @entity230 alone. Finally, these results suggest that in many @entity1 therapy may have to be prolonged before a remission can be observed.
